Its not strange at all. They've identified an opportunity (hsv-2 vaccine) and they're pursuing it. Opportunities don't last forever - Sure you could wait five years until ADAPT is raking in the cash but then somebody else will have made it to market first. Obviously Rodne's spending was a bit out of control but i'd much rather have too many growth opportunities and have to control costs for a few years in the beginning. The alternative to investing in growth opportunities is paying out dividends for 15 years and having the company burn out when the ADAPT patent expires. THAT is a strange way to run a business.
AHZ is 2 companies -why not split into 2?, page-27
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.65 |
Change
-0.350(2.33%) |
Mkt cap ! $309.6M | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.94 | $14.25 | $1.266M | 86.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 126 | $14.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.65 | 99 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |